Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ:SUPN) ("Supernus", and the "Company"), today ann...
Scotiabank analyst George Farmer downgrades Sage Therapeutics (NASDAQ:SAGE) from Sector Outperform to Sector Perform and low...
Baird analyst Joel Beatty maintains Sage Therapeutics (NASDAQ:SAGE) with a Neutral and raises the price target from $7 to $9.
Piper Sandler analyst David Amsellem downgrades Sage Therapeutics (NASDAQ:SAGE) from Overweight to Neutral and lowers the pr...
Truist Securities analyst Joon Lee maintains Sage Therapeutics (NASDAQ:SAGE) with a Hold and raises the price target from $8...
